FDA Approval of Adjuvant Sunitinib for Renal Cell Cancer

This Viewpoint examines the data and circumstances behind the US Food and Drug Administration approval of sunitinib as adjuvant treatment for patients with resected renal cell carcinoma who are at a high risk of relapse.

http://ift.tt/2HecHRR